NG 796A
Alternative Names: NG-796ALatest Information Update: 25 Apr 2023
At a glance
- Originator Akamis Bio
- Class Antineoplastics; Gene therapies; Immunotherapies
- Mechanism of Action Gene transference; Natural killer cell stimulants; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Solid tumours
Most Recent Events
- 14 Apr 2023 Preclinical trials in Solid tumors in United Kingdom (IV), prior to April 2023 (Akamis Bio pipeline, April 2023)